RT杂志文章SR Electronic T1静脉注射甲基强的松龙脉冲治疗住院重症COVID-19患者:随机对照临床试验结果摩根富林明欧洲呼吸杂志乔和J FD欧元欧洲呼吸学会SP 2002808 10.1183/13993003.02808 -2020签证官56是6 A1 Edalatifard Maryam188bet官网地址 A1 Akhtari, Maryam A1萨利希,Mohammadreza A1 Naderi, Zohre A1卷Ahmadreza A1米斯塔费尔,扎A1 Najafizadeh,Seyed Reza A1 Farhadi, Elham A1 Jalili, noshin A1 Esfahani, Masoud A1 Rahimi, Besharat A1 Kazemzadeh, Hossein A1 mahmodi Aliabadi, madeh A1 Ghazanfari, Tooba A1 satarian, Mohammadreza A1 Ebrahimi Louyeh, Hourvash A1 Raeeskarami, Seyed Reza A1 Jamalimoghadamsiahkali, Saeidreza A1 Khajavirad, Nasim A1 Mahmoudi, Mahdi A1 Rostamian，目前还没有确定的治疗重症COVID-19的药物。提示甲强的松龙作为一种免疫抑制疗法，可减轻COVID-19患者呼吸系统炎症。方法:我们进行了一项单盲、随机对照临床试验，涉及伊朗确诊COVID-19早期肺部阶段的重症住院患者。患者按1:1的比例随机分组，接受甲基泼尼松龙脉冲(静脉注射，250 mg·d - 1，连续3天)或单独接受标准治疗。研究终点为临床改善或死亡时间，以先到者为准。初步和安全性分析是在意向治疗(ITT)人群中进行的。从2020年4月20日至2020年6月20日，68例符合条件的患者进行了随机分组(每组34例)。 In the standard care group, six patients received corticosteroids by the attending physician before the treatment and were excluded from the overall analysis. The percentage of improved patients was higher in the methylprednisolone group than in the standard care group (94.1% versus 57.1%) and the mortality rate was significantly lower in the methylprednisolone group (5.9% versus 42.9%; p<0.001). We demonstrated that patients in the methylprednisolone group had a significantly increased survival time compared with patients in the standard care group (log-rank test: p<0.001; hazard ratio 0.293, 95% CI 0.154–0.556). Two patients (5.8%) in the methylprednisolone group and two patients (7.1%) in the standard care group showed severe adverse events between initiation of treatment and the end of the study.Conclusions Our results suggest that methylprednisolone pulse could be an efficient therapeutic agent for hospitalised severe COVID-19 patients at the pulmonary phase.This study showed that methylprednisolone pulse administration at the beginning of the early pulmonary phase of illness decreased the mortality rate and improved pulmonary involvement, oxygen saturation and inflammatory markers in COVID-19 patients https://bit.ly/3hik4JB